However, as several clinical trials have shown (10, 52–55), certain bacteria might stimulate the innate immune response in ICI responders, leading to CXCL9 production in the TME and sensitization of anti–PD-1 antibody treatment through recruitment of tumor-specific CD8+ T cells. The gene discussed is CXCL9; the disease is neoplasm.